# A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

> **NCT04449276** · PHASE1 · COMPLETED · sponsor: **CureVac** · enrollment: 280 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome
- Coronavirus
- SARS-CoV-2
- COVID-19

## Interventions

- **BIOLOGICAL:** CVnCoV Vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04449276
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2021-12-21
- **Final completion:** 2021-12-21
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04449276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04449276, "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04449276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*